Comparison of patient characteristics at initiation of imatinib
Patient characteristics . | Patients with deletions, n = 59 (%) . | Patients without deletions, n = 338 (%) . | P . |
|---|---|---|---|
| Disease phase | |||
| BC | 11 (18) | 57 (18) | .3 |
| AP | 4 (7) | 50 (15) | |
| CP1, IFN failure | 33 (57) | 191 (55) | |
| CP1, newly diagnosed | 11 (18) | 40 (12) | |
| Available IFN response | 41 | 210 | |
| Newly diagnosed | 8 (20) | 34 (16) | .09 |
| Hematologic resistance | 2 (5) | 15 (7) | |
| Hematologic relapse | 6 (15) | 9 (4) | |
| Cytogenetic resistance | 9 (21) | 80 (38) | |
| Cytogenetic relapse | 12 (29) | 46 (22) | |
| IFN intolerant | 4 (10) | 26 (13) | |
| Weight, available | 24 | 122 | |
| Less than 70 kg | 7 (29) | 39 (32) | .78 |
| More than 70 kg | 17 (71) | 83 (68) | |
| Splenomegaly | 17/42 (40) | 110/211 (52) | .17 |
| Platelet count, available | 38 | 172 | |
| Less than 450 × 109/L | 32 (85) | 119 (69) | .16 |
| 450-699 × 109/L | 2 (5) | 32 (19) | |
| More than 700 × 109/L | 4 (10) | 21 (12) | |
| Hb, available | 39 | 199 | |
| Less than 12 g/dL | 20 (51) | 97 (49) | .88 |
| More than 12 g/dL | 19 (49) | 102 (51) | |
| WCC, available | 44 | 218 | |
| Less than 10 × 109/L | 21 (48) | 97 (44) | .37 |
| 10-49.9 × 109/L | 21 (48) | 95 (43) | |
| More than 50 × 109/L | 2 (4) | 26 (13) | |
| PB blasts, available | 34 | 155 | |
| 0 | 29 (85) | 106 (68) | .07 |
| 0-2 | 0 | 15 (9) | |
| More than 3 | 5 (15) | 34 (23) | |
| BM blasts, available | 34 | 153 | |
| Less than 5 | 29 (85) | 105 (68) | .12 |
| More than 5 | 5 (15) | 48 (32) | |
| Ph positive metaphases, available | 51 | 291 | |
| Less than 90 | 8 (16) | 53 (18) | .66 |
| More than 90 | 43 (84) | 238 (82) | |
| Additional cytogenetic abnormalities | 15/59 (25) | 73/331 (22) | .66 |
Patient characteristics . | Patients with deletions, n = 59 (%) . | Patients without deletions, n = 338 (%) . | P . |
|---|---|---|---|
| Disease phase | |||
| BC | 11 (18) | 57 (18) | .3 |
| AP | 4 (7) | 50 (15) | |
| CP1, IFN failure | 33 (57) | 191 (55) | |
| CP1, newly diagnosed | 11 (18) | 40 (12) | |
| Available IFN response | 41 | 210 | |
| Newly diagnosed | 8 (20) | 34 (16) | .09 |
| Hematologic resistance | 2 (5) | 15 (7) | |
| Hematologic relapse | 6 (15) | 9 (4) | |
| Cytogenetic resistance | 9 (21) | 80 (38) | |
| Cytogenetic relapse | 12 (29) | 46 (22) | |
| IFN intolerant | 4 (10) | 26 (13) | |
| Weight, available | 24 | 122 | |
| Less than 70 kg | 7 (29) | 39 (32) | .78 |
| More than 70 kg | 17 (71) | 83 (68) | |
| Splenomegaly | 17/42 (40) | 110/211 (52) | .17 |
| Platelet count, available | 38 | 172 | |
| Less than 450 × 109/L | 32 (85) | 119 (69) | .16 |
| 450-699 × 109/L | 2 (5) | 32 (19) | |
| More than 700 × 109/L | 4 (10) | 21 (12) | |
| Hb, available | 39 | 199 | |
| Less than 12 g/dL | 20 (51) | 97 (49) | .88 |
| More than 12 g/dL | 19 (49) | 102 (51) | |
| WCC, available | 44 | 218 | |
| Less than 10 × 109/L | 21 (48) | 97 (44) | .37 |
| 10-49.9 × 109/L | 21 (48) | 95 (43) | |
| More than 50 × 109/L | 2 (4) | 26 (13) | |
| PB blasts, available | 34 | 155 | |
| 0 | 29 (85) | 106 (68) | .07 |
| 0-2 | 0 | 15 (9) | |
| More than 3 | 5 (15) | 34 (23) | |
| BM blasts, available | 34 | 153 | |
| Less than 5 | 29 (85) | 105 (68) | .12 |
| More than 5 | 5 (15) | 48 (32) | |
| Ph positive metaphases, available | 51 | 291 | |
| Less than 90 | 8 (16) | 53 (18) | .66 |
| More than 90 | 43 (84) | 238 (82) | |
| Additional cytogenetic abnormalities | 15/59 (25) | 73/331 (22) | .66 |
For those patients in whom information was available at the initiation of imatinib, there were no significant differences between patients with and without deletions (P as shown). IFN indicates interferon-α; PB, peripheral blood; BM, bone marrow; WCC, white cell count; Hb, hemoglobin.